Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.50 |
| ▸ | TUBB | P07437 | 3/20 | 0.50 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.50 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.50 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.50 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.50 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.50 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.50 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.50 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.50 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.50 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1715075 | 0.98 | PTGS2 (0.57) | PTGS2HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL7961363 | 0.82 | PTGS2 (0.64) | PTGS2HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL7959757 | 0.82 | PTGS2 (0.64) | PTGS2HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL11841088 | 0.78 | PTGS2 (0.59) | PTGS2HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL7959754 | 0.78 | PTGS2 (0.59) | PTGS2HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL111191 | 0.77 | HTR2A (0.69) | PTGS2HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL31432799 | 0.77 | PTGS2 (0.63) | PTGS2HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL11008456 | 0.77 | CA2 (0.63) | CYP3A4AOC3CYP19A1ABCB1IDO1 | |
| SCHEMBL4464142 | 0.77 | HTR2A (0.75) | PTGS2HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL8910416 | 0.77 | PTGS2 (0.70) | PTGS2HTR2AHTR2CHTR2BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | claimed |
| CN-1906155-A | Novel hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA AS (DK) | 2007-01-31 | — | — | CN | claimed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| CN-1906155-B | Novel hydroxamic acid ester derivant and pharmaceutical use thereof | LEO PHARMA AS | 2010-06-23 | — | — | CN | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| CN-1906155-A | Novel hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA AS (DK) | 2007-01-31 | — | — | CN | disclosed |
| EP-1266887-B1 | Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-08-17 | — | — | EP | disclosed |
| EP-1266887-A2 | Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | PTGS2 1912/4885HTR2A 2326/4885HTR2C 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.